G40.C01
Lafora progressive myoclonus epilepsy, not intractable, with status epilepticus
Clinical Classification Guidelines
Medical Intelligence & Overview
Lafora progressive myoclonus epilepsy (PME) is a rare and hereditary neurological disorder characterized by the development of myoclonus, seizures, and neurological decline over time. Classified under ICD-10 code G40.C01, this condition is distinguished by its progressive nature and the presence of status epilepticus, a severe and prolonged seizure state that requires immediate medical attention. Unlike other forms of epilepsy, Lafora disease manifests with a specific pattern of neurological deterioration that typically begins in adolescence and worsens over the years, impacting quality of life significantly.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting genes responsible for carbohydrate metabolism, particularly the EPM2A and NHLRC1 (Malin) genes. Inheritance in an autosomal recessive pattern, meaning both copies of the gene must be altered for the disease to manifest. Presence of abnormal deposits of polyglucosans called Lafora bodies in brain tissues, contributing to neuronal dysfunction.
Key Symptoms: Myoclonus: sudden, involuntary muscle jerks often affecting muscles in the limbs, face, or trunk. Seizures: variety including generalized tonic-clonic, absence, or focal seizures. Progressive neurological decline: including cognitive impairment, decline in motor skills, and loss of independence. Visual disturbances: such as visual hallucinations or difficulty with coordination and balance. Sleep disturbances: including insomnia or abnormal sleep patterns. Status epilepticus: a prolonged or repeated seizure state that can be life-threatening if not promptly treated.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, family history assessment, and various diagnostic tests. Key components include: - Detailed neurological examination to assess seizure activity and neurological deficits. - Electroencephalogram (EEG) to identify characteristic abnormal brain activity patterns. - Brain imaging studies like MRI to rule out other causes of neurological symptoms. - Detection of Lafora bodies in skin or brain tissues via biopsy. - Genetic testing to identify mutations in EPM2A or NHLRC1 genes, confirming the diagnosis.
Treatment Protocols: While there is currently no cure for Lafora disease, management focuses on controlling symptoms and improving quality of life. Treatment options include: - Antiepileptic drugs (AEDs) to reduce seizure frequency and severity. - Medications aimed at controlling myoclonus. - Supportive therapies like physical, occupational, and speech therapy to assist with motor and communication skills. - Regular monitoring for neurological deterioration. - Emergency management strategies for status epilepticus, including administration of rescue medications. - Participation in clinical trials exploring novel therapies may also be considered. It is important to remember that treatment plans should always be tailored to individual patient needs under medical supervision.
Clinical Advice & FAQs
Billing Guidance
Is G40.C01 a billable ICD-10 code?
Yes, G40.C01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G40.C01?
Clinical documentation must specify the nature of Lafora progressive myoclonus epilepsy, not intractable, with status epilepticus and any associated comorbidities for accurate reporting.
Cite this Clinical Reference